462 Molecular Features of IDH-Wild Type Glioblastoma in Extreme Survival Poles Following Supramaximal and Maximal Resection: A Single-Institution Retrospective Cohort Study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: IDH-Wild Type Glioblastoma (IDH-WT GBM) remains a brain tumor with poor prognosis. Even with optimal treatment, survival remains unpredictable, with 15–23.9% experiencing short-term survival (STS) and 2–5% long-term survival (LTS). METHODS: We retrospectively analyzed newly-diagnosed IDH-WT GBM patients who underwent high resection categories (supramaximal or complete contrast-enhancing resection) per RANO, received chemoradiotherapy with temozolomide, and underwent Next-Generation sequencing targeting 315 tumor-associated genes (2009–2025). Patients were categorized as STS (survival ≤12 months), non-STS (survival >12 months) or LTS (survival ≥36 months). The study compared clinical, radiological, and molecular features. RESULTS: Eighty-five IDH-WT GBM patients met the inclusion criteria. From these, 24 (28%) were STS, and 61 were non-STS (from which 16 [18.8%] were LTS). Tumor location varied, with STS patients having more frontal lobe tumors (45.8 vs. 0%, p = 0.010) and LTS patients having more temporal lobe tumors (62.5 vs. 25%, p=0.020). Although non-local recurrence trended to STS (27.2% vs. 16.6%), this difference did not reach significance. When comparing STS and LTS, CDKN2A/B loss (83.3% vs. 43.8%, p = 0.010) and EGFR amplification (58.3% vs. 25%, p = 0.050) were more frequent in STS. Univariate and multivariate analyses of overall survival confirmed the same two mutations associated with increased STS risk: CDKN2A/B loss (HR = 1.86, CI = 1.06–3.29, p = 0.030) and EGFR amplification (HR = 1.69, CI = 1.06–2.71, p = 0.020). CONCLUSIONS: Despite aggressive extent-of-resection in IDH-WT GBM, STS remains high (∼28%) while LTS is limited (∼18.8%). Frontal tumors linked to higher STS rates, while temporal tumors to LTS. CDKN2A/B loss and EGFR amplification, previously linked to poor outcomes in IDH-mutant Astrocytomas, significantly increase STS risk after high resection categories, reveal novel molecular factors influencing survival poles in IDH-WT GBM, and hold promise for prognostic markers or therapeutic targets.
Fields of Study & Subjects
Glioma Diagnosis and Treatment
Radiomics and Machine Learning in Medical Imaging
Ovarian cancer diagnosis and treatment
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 135–135
- Publication date
- 26 March 2026
- Language
- EN